Efficacy outcome selection in the therapeutic hypothermia after pediatric cardiac arrest trials

Richard Holubkov1, Amy E Clark, Frank W Moler

  • 11Department of Pediatrics, University of Utah, Salt Lake City, UT. 2Department of Pediatrics, University of Michigan, Ann Arbor, MI. 3Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, MD. 4Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD. 5Department of Pediatric Rehabilitation Medicine, Kennedy Krieger Institute, Baltimore, MD. 6Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD. 7Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. 8Department of Pediatrics, Wayne State University, Detroit, MI. 9Division of Critical Care Medicine, Children's National Medical Center, Washington, DC. 10Department of Pediatrics, George Washington University School of Health Sciences, Washington, DC.

Insights

Therapeutic hypothermia after pediatric cardiac arrest improves survival with good neurobehavioral outcomes. The study selected a 12-month assessment with a binary outcome for optimal trial design.

Area of Science:

  • Pediatric critical care medicine
  • Neuroscience
  • Clinical trial design

Background:

  • Pediatric cardiac arrest (PCA) poses significant challenges for survival and neurobehavioral recovery.
  • Therapeutic hypothermia (TH) is a potential intervention to improve outcomes after PCA.
  • Optimizing outcome measures is crucial for evaluating the efficacy of TH in pediatric populations.

Purpose of the Study:

  • To determine if therapeutic hypothermia improves survival with good neurobehavioral outcome in children after cardiac arrest.
  • To describe the process of selecting efficacy outcomes for the Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPPCA) trials.
  • To establish optimal timing and methods for assessing neurobehavioral function post-resuscitation.

Main Methods:

  • Consensus-based assessment of potential outcomes and evaluation timepoints.
  • Simulations to estimate statistical power based on varying hypothermia benefits.
  • Evaluation of continuous/categorical outcome variants and pre-arrest status incorporation.

Main Results:

  • Twelve months post-arrest was selected as the optimal assessment timepoint for pragmatic and clinical reasons.
  • A primary outcome of survival with a 12-month Vineland Adaptive Behavior Scales Second Edition score of no less than 70 was chosen.
  • Two secondary outcomes include 12-month survival and quasicontinuous neurobehavioral change, evaluated in all randomized children.

Conclusions:

  • Extensive discussion on efficacy assessment timing and outcome measures informed the THAPPCA trial design.
  • A relatively simple, binary primary outcome assessed at 12 months was selected for the trial.
  • Secondary outcomes were included to address potential limitations of the primary outcome and capture broader functional changes.
Abstract